Ken Drazan, ArsenalBio CEO
ArsenalBio lands $70M cash deal with cancer giant Genentech to develop cell therapy
San Francisco-based ArsenalBio’s designer T cells program is attracting the attention of some big players.
After closing a deal and grabbing $70 million in cash …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.